PharmaShots | Incisive News in 3 Shots

Subscribe Now

InnoCare

InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients

InnoCare Receives IND Approval from NMPA to Initiate P-I Study of ICP-189 + Furmonertinib in NSCLC Patients

September 14, 2023

InnoCare Entered into a Clinical Development Collaboration with ArriVent to Evaluate ICP-189 + Furmonertinib for Advanced Non-Small Cell Lung Cancer

InnoCare Entered into a Clinical Development Collaboration with ArriVent to Evaluate ICP-189 + Furmonertinib for Advanced Non-Smal...

July 14, 2023

InnoCare Reports the First Patient Dosing of ICP-488 in Clinical Trial for the Treatment of Psoriasis in China

InnoCare Reports the First Patient Dosing of ICP-488 in Clinical Trial for the Treatment of Psoriasis in China

July 5, 2023

$InnoCare’s Orelabrutinib Receives the NMPA’s Approval for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma$

InnoCare’s Orelabrutinib Receives the NMPA’s Approval for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma

April 20, 2023

PharmaShots Weekly Snapshots (July 18 – 22, 2022)

PharmaShots Weekly Snapshots (July 18 – 22, 2022)

July 22, 2022

InnoCare’s Tafasitamab + Lenalidomide Receives Approval from China Regulatory Authority to Treat r/r Diffuse Large B-Cell Lymphoma

InnoCare’s Tafasitamab + Lenalidomide Receives Approval from China Regulatory Authority to Treat r/r Diffuse Large B-Cell Lymphoma

July 22, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us